Successful rechallenge for oxaliplatin hypersensitivity reactions in patients with metastatic colorectal cancer

Anticancer Research

Volumn 32, Issue 12, 2012, Pages 5521-5526

  Yanai, Takako ^a   Iwasa, Satoru ^a   Hashimoto, Hirhonobu ^a   Kato, Ken ^a   Hamaguchi, Tetsuya ^a   Yamada, Yasuhide ^a   Shimada, Yasuhiro ^a   Yamamoto, Hiroshi ^a  

^a NATIONAL CANCER CENTER HOSPITAL   (Japan)

Author keywords

Colorectal cancer; Epinephrine; Hypersensitivity; Oxaliplatin; Rechallenge

Indexed keywords

ADRENALIN; CHLORPHENIRAMINE; HYDROCORTISONE; OXALIPLATIN; RANITIDINE;

ADULT; AGED; ARTICLE; CANCER PATIENT; CLINICAL PROTOCOL; COLORECTAL CANCER; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG HYPERSENSITIVITY; DRUG RECHALLENGE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; CHLORPHENIRAMINE; COLORECTAL NEOPLASMS; DRUG HYPERSENSITIVITY; EPINEPHRINE; FEMALE; HUMANS; HYDROCORTISONE; MALE; MIDDLE AGED; NEOPLASM METASTASIS; ORGANOPLATINUM COMPOUNDS; RANITIDINE; RETROSPECTIVE STUDIES;

EID: 84872548985     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (21)

1. de Gramont A, Figer A, Seymour M, Homerin M, Hmissi A, Cassidy J, Boni C, Cortes-Funes H, Cervantes A, Freyer G, Papamichael D, Le Bail N, Louvet C, Hendler D, de Braud F, Wilson C, Morvan F and Bonetti A: Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 18: 2938-2947, 2000.
2. Goldberg RM, Sargent DJ, Morton RF, Fuchs CS, Ramanathan RK, Williamson SK, Findlay BP, Pitot HC and Alberts SR: A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 22: 23-30, 2004.
3. Saltz LB, Clarke S, Díaz-Rubio E, Scheithauer W, Figer A, Wong R, Koski S, Lichinitser M, Yang TS, Rivera F, Couture F, Sirzén F and Cassidy J: Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: A randomized phase III study. J Clin Oncol 26: 2013-2019, 2008.
4. Tournigand C, André T, Achille E, Lledo G, Flesh M, Mery-Mignard D, Quinaux E, Couteau C, Buyse M, Ganem G, Landi B, Colin P, Louvet C and de Gramont A: FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: A randomized GERCOR study. J Clin Oncol 22 : 229-237, 2004.
5. Rothenberg ML, Oza AM, Bigelow RH, Berlin JD, Marshall JL, Ramanathan RK, Hart LL, Gupta S, Garay CA, Burger BG, Le Bail N and Haller DG: Superiority of oxaliplatin and fluorouracil-leucovorin compared with either therapy alone in patients with progressive colorectal cancer after irinotecan and fluorouracil-leucovorin: interim results of a phase III trial. J Clin Oncol 21: 2059-2069, 2003.
6. André T, Boni C, Mounedji-Boudiaf L, Navarro M, Tabernero J, Hickish T, Topham C, Zaninelli M, Clingan P, Bridgewater J, Tabah-Fisch I and de Gramont A; Multicenter International Study of Oxaliplatin/5-Fluorouracil/ Leucovorin in the Adjuvant Treatment of Colon Cancer (MOSAIC) Investigators: Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med 350 : 2343-2351, 2004.
7. Cunningham D, Starling N, Rao S, Iveson T, Nicolson M, Coxon F, Middleton G, Daniel F, Oates J and Norman AR; Upper Gastrointestinal Clinical Studies Group of the National Cancer Research Institute of the United Kingdom: Capecitabine and oxaliplatin for advanced esophagogastric cancer. N Engl J Med 358: 36-46, 2008.
8. Al-Batran SE, Hartmann JT, Probst S, Schmalenberg H, Hollerbach S, Hofheinz R, Rethwisch V, Seipelt G, Homann N, Wilhelm G, Schuch G, Stoehlmacher J, Derigs HG, Hegewisch-Becker S, Grossmann J, Pauligk C, Atmaca A, Bokemeyer C, Knuth A and Jäger E; Arbeitsgemeinschaft Internistische Onkologie: Phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil, leucovorin plus either oxaliplatin or cisplatin: A study of the Arbeitsgemeinsche Onkologie. J Clin Oncol 26: 1435-1442, 2008.
9. Pelzer U, Schwaner I, Stieler J, Adler M, Seraphin J, Dörken B, Riess H and Oettle H: Best supportive care (BSC) versus oxaliplatin, folinic acid and 5-fluorouracil (OFF) plus BSC in patients for second-line advanced pancreatic cancer: A phase III study from the German CONKO-study group. Eur J Cancer 47: 1676-1681, 2011.
10. Conroy T, Desseigne F, Ychou M, Bouché O, Guimbaud R, Bécouarn Y, Adenis A, Raoul JL, Gourgou-Bourgade S, de la Fouchardière C, Bennouna J, Bachet JB, Khemissa-Akouz F, Péré-Vergé D, Delbaldo C, Assenat E, Chauffert B, Michel P, Montoto-Grillot C and Ducreux M; Groupe Tumeurs Digestives of Unicancer; PRODIGE Intergroup: FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med 364: 1817-1825, 2011.
11. Shepherd GM: Hypersensitivity reactions to chemotherapeutic drugs. Clin Rev Allergy Immunol 24: 253-262, 2003.
12. Thomas RR, Quinn MG, Schuler B and Grem JL: Hypersensitivity and idiosyncratic reactions to oxaliplatin. Cancer 97 : 2301-2307, 2003.
13. Brandi G, Pantaleo MA, Galli C, Falcone A, Antonuzzo A, Mordenti P, Di Marco MC and Biasco G: Hypersensitivity reactions related to oxaliplatin (OHP). Br J Cancer 89: 477-481, 2003.
14. Siu SW, Chan RT and Au GK: Hypersensitivity reactions to oxaliplatin: Experience in a single institute. Ann Oncol 17: 259-261, 2006.
15. Polyzos A, Tsavaris N, Kosmas C, Gogas H, Toufexi H, Kosmidis C, Markopoulos C, Giannopoulos A, Papadopoulos O, Stamatiadis D and Kouraklis G: Clinical features of hypersensitivity reactions to oxaliplatin: A 10-year experience. Oncology 76: 36-41, 2009.
16. Kim BH, Bradley T, Tai J and Budman DR: Hypersensitivity to oxaliplatin: An investigation of incidence and risk factors, and literature review. Oncology 76: 231-238, 2009.
17. Maindrault-Goebel F, André T, Tournigand C, Louvet C, Perez-Staub N, Zeghib N and De Gramont A: Allergic-type reactions to oxaliplatin: Retrospective analysis of 42 patients. Eur J Cancer 41 : 2262-2267, 2005.
18. Cancer Therapy Evaluation Program, Common Terminology Criteria for Adverse Events, Version 3.0, DCTD, NCI, NIH, DHHS March 31, 2003. Available at: http://ctep.cancer.gov. Publish Date: August 9, 2006.
19. Syrigou EI, Karapanagiotou EM, Alamara CV, Boura PG, Saif MW and Syrigos KN: Hypersensitivity reactions to oxaliplatin: A retrospective study and the development of a desensitization protocol. Clinical Colorectal Cancer 8 : 106-109, 2009.
20. Rakkar AS: Management of hypersensitivity reactions to oxaliplatin with SC epinephrine. Gastrointestinal Cancers Symposium abstract 258, 2006.
21. Iwasa S, Hamaguchi T, Tada K, Yanai T, Hashimoto H, Nakajima TE, Kato K, Yamada Y and Shimada Y: Prophylactic administration of epinephrine in oxaliplatin-related hypersensitivity reaction. J Clin Oncol 29(suppl 4): abstr 610, 2011.